An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy - Report - MDSpire
Advertisement
An expression signature of 19 human endogenous retroviruses identifies immunogenic luminal breast cancers likely to respond to immunotherapy
Clinical Report: A 19 HERV Expression Profile Identifies Luminal Breast Cancer Subtypes
Overview
This study identifies a specific 19 HERV expression signature associated with tumor immunogenicity in HR+HER2− early breast cancer.
Background
Human endogenous retroviruses (HERVs) represent a significant portion of the human genome and can be re-expressed in cancer cells, potentially influencing immune responses.
Data Highlights
No numerical data or trial data was provided in the source material.
Key Findings
Overall HERV tumor load does not significantly vary among different early breast cancer subtypes.
A 19 HERV expression signature, termed “Breast HERV19,” is associated with signs of tumor immunogenicity.
Expression of the HERV19 signature is linked to biomarkers of sensitivity to anti-PD-1 immunotherapy, including tumor-infiltrating lymphocytes (TILs) and PD-L1 levels.
Clinical Implications
The identification of the Breast HERV19 expression signature may assist clinicians in stratifying HR+HER2− early breast cancer patients for immunotherapy.
Conclusion
The Breast HERV19 expression signature may guide future immunotherapy strategies.
